912 related articles for article (PubMed ID: 11571832)
1. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
2. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
3. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
Hinz B; Brune K
Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
[TBL] [Abstract][Full Text] [Related]
4. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
5. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
7. COX-2 inhibitors.
Brooks PM; Day RO
Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
9. [Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Hinz B; Brune K
MMW Fortschr Med; 2000 Mar; 142(11):39-40. PubMed ID: 10786088
[No Abstract] [Full Text] [Related]
10. New NSAIDs and gastroduodenal damage.
Folco GC
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
[TBL] [Abstract][Full Text] [Related]
11. COX-2-specific inhibition: implications for clinical practice.
Pascucci RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
[TBL] [Abstract][Full Text] [Related]
12. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
[TBL] [Abstract][Full Text] [Related]
13. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
14. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
Pairet M; Netter P
Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
[TBL] [Abstract][Full Text] [Related]
15. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
17. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
18. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
19. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
Patrignani P
Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
